Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - Relationship with clinical outcome

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1153-1161

  Ferroni, Patrizia ^a   Roselli, Mario ^b   Portarena, Ilaria ^b   Formica, Vincenzo ^b   Riondino, Silvia ^b   La Farina, Francesca ^c   Costarelli, Leopoldo ^d   Melino, Antonia ^a   Massimiani, Gioia ^b   Cavaliere, Francesco ^d   Palmirotta, Raffaele ^a   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Ceglie Messapica Hospital   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

Author keywords

Breast cancer; D dimer; Overall survival; Plasminogen activator inhibitor 1; Relapse free survival

Indexed keywords

ACTIVATED PROTEIN C; ANTHRACYCLINE; AROMATASE INHIBITOR; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; THROMBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COAGULATION ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; EVALUATION STUDY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; BLOOD; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; D-DIMER; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG CARCINOMA; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PLASMINOGEN ACTIVATOR INHIBITOR-1; RELAPSE-FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST CANCER; D-DIMER; OVERALL SURVIVAL; PLASMINOGEN ACTIVATOR INHIBITOR-1; RELAPSE-FREE SURVIVAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899682350     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bick RL: Cancer-associated thrombosis. N Engl J Med 349: 109-111, 2003.
2. Tsopanoglou NE and Maragoudakis ME: Thrombin's central role in angiogenesis and pathophysiological processes. Eur Cytokine Netw 20(4): 171-179, 2009.
3. Tang L and Han X: The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67(2): 179-182, 2013.
4. Kwaan HC, Mazar AP and McMahon BJ: The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 39(4): 382-391, 2013.
5. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H and Schmitt M; German N0 Study Group. German N0 Study Group: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920, 2001.
6. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernó M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Bróner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broó P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M and Foekens JA: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002.
7. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M and Foekens JA: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 62: 4617-4622, 2002.
8. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP and Foekens JA: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5: 348-352, 2004.
9. Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA and Werb Z: Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomark Prev 15: 2107-2114, 2006.
10. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F and Thomssen C; Chemo-N 0 Study Group: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)- recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 49(8): 1825-1835, 2013.
11. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr.: American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol 25(33): 5287-5312, 2007.
12. Patani N, Martin LA and Dowsett M: Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 133(1): 1-13, 2013.
13. Chung HC, Rha SY, Park JO, Yoo NC, Kim JH, Roh JK, Min JS, Lee KS, Kim BS and Kim JJ: Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Res Treat 49: 41-50, 1998.
14. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P and Lip GY: Increased soluble P-selectin in patients with haematological and breast cancer: A comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 12: 43-50, 2001.
15. Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG and Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration. Oncol Rep 14: 235-239, 2005.
16. Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Fossile E, Del Monte G, Guadagni F and Roselli M: Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer. Thromb Res 124: 403-408, 2009.
17. Mytnik M and Stasko J: D-dimer, plasminogen activator inhibitor- 1, prothrombin fragments and protein C-role in prothrombotic state of colorectal cancer. Neoplasma 58(3): 235-238, 2011.
18. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS and Greene FL: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20: 3628-3636, 2002.
19. Ferroni P, La Farina F, Palmirotta R, Martini F, Raparelli V, Nigro C, Riondino S, Rampini MR, Basili S and Guadagni F: Predictive value of ThromboPath determination in women with pregnancy complications. Clin Chim Acta 411: 37-42, 2010.
20. Ferroni P, Martini F, Portarena I, Massimiani G, Riondino S, La Farina F, Mariotti S, Guadagni F and Roselli M: Novel highsensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in lung cancer patients. Clin Lung Cancer 13(6): 482-487, 2012.
21. Rak J, Yu JL, Luyendyk J and Mackman N: Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66: 10643-6, 2006.
22. Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C and Harbeck N: Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in nodenegative primary breast cancer. Breast Cancer Res Treat 138(3): 839-850, 2013.
23. Jacobs VR, Augustin D, Wischnik A, Kiechle M, Höss C, Steinkohl O, Rack B, Kapitza T and Krase P: Prospective multicenter study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer. Breast 22(4): 436-443, 2013.
24. Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A, Lisboa B, Jaenicke F, Schmitt M and Vetter M: Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst 101(14): 1028-1029, 2009.
25. Beyan C: Is mean platelet volume a predictive marker in patients with venous thrombosis? Clin Appl Thromb Hemost 18: 670-671, 2012.
26. Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M and Gion M: Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 16: 87-96, 2001.
27. Nanni U, Spila A, Riondino S, Valente MG, Somma P, Iacoboni M, Alessandroni J, Papa V, Della-Morte D, Palmirotta R, Ferroni P, Roselli M and Guadagni F: RFID as a new ICT tool to monitor specimen life cycle and quality control in a biobank. Int J Biol Markers 26: 129-135, 2011.
28. Nanni U, Betsou F, Riondino S, Rossetti L, Spila A, Valente MG, Della-Morte D, Palmirotta R, Roselli M, Ferroni P and Guadagni F: SPRECware: Software tools for Standard PREanalytical Code (SPREC) labelling: Effective exchange and search of stored biospecimens. Int J Biol Markers 27: e272-279, 2012.
29. Carter JC, Campbell RA, Gibbons JA, Gramling MW, Wolberg AS and Church FC: Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells. J Thromb Haemost 8(6): 1323-1332, 2010.
30. Zheng D, Chen H, Davids J, Bryant M and Lucas A: Serpins for diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets 13(2): 123-132, 2013.
31. Che DH, Cao JY, Shang LH, Man YC and Yu Y: The efficacy and safety of low-molecular-weight heparin use for cancer treatment: A meta-analysis. Eur J Intern Med 24(5): 433-439, 2013.
32. Zheng D, Chen H, Davids J, Bryant M and Lucas A: Serpins for diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets 13(2): 123-132, 2013.
33. Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H and Kohno N: SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther 12(11): 2378-2388, 2013.